BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Sun Pharmaceutical Industries Ltd.'s revenues grew 11% YoY to Rs 10762 crore (excluding Covid products sales for Q1 last year, overall sales up by 14%).
Indian formulations grew 2% YoY to Rs 3387 crore, while excluding Covid sales in Q1 FY22, India formulations grew by 13%.
Sun Pharma's U.S. formulations grew to Rs 3244 crore, up 16% YoY as the specialty business has grown by 29% YoY to $191 million. Emerging Markets business grew 18% YoY to Rs 1891 crore. Rest of World Markets business grew 7% YoY to Rs 1468 crore.
Active pharma ingredient segment posted growth of 11% YoY to Rs 654 crore. Ebitda margins declined 223 basis points YoY, amid lower margins from Taro in Q1, and stood at 26.8% on back of higher employee and other expenses on a low base of Q1 FY22 and Alchemee consolidation.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.